ΚΑΡΑΔΗΜΟΥ ΑΛΕΞΑΝΔΡΑ

Κατηγορία: ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ

Παθολόγος – Ογκολόγος

211 9904357

προφιλ

Αναπληρώτρια Διευθύντρια της ΣΤ’ Ογκολογικής Κλινικής του Metropolitan General

ΕΚΠΑΙΔΕΥΣΗ & ΑΚΑΔΗΜΑΪΚΟΙ ΤΙΤΛΟΙ

Ιατρική Σχολή Πανεπιστημίου Πατρών, 1995-2001
A.T.L.S (ADVANCED TRAUMA & LIFE SUPPORT) American college of Surgeons – Αρχές Αντιμετώπισης πολυτραυματιών του Αμερικανικού Κολεγίου Χειρουργών, 2003
Εξετάσεις πιστοποίησης ειδικότητας Παθολογικής Ογκολογίας, Αθήνα, 2011
Research fellowship για τον καρκίνο, University of Paris Descartes, Hôpital Européen Georges Pompidou and ΙNSERM unit 674, Παρίσι, 2010-2012
Διδάκτωρ Ιατρικής Σχολής Πανεπιστημίου Αθηνών, 2014
Μεταπτυχιακό ‘’Advanced Leadership & Negotiation Skills’’, Εθνικό Καποδιστριακό Πανεπιστήμιο Αθηνών, 2022

ΠΡΟΫΠΗΡΕΣΙΑ

Παθολόγος Ογκολόγος, Ιατρικό κέντρο Αθηνών, 06.2023-11.2025
Medical Lead Oncology-Hematology, AstraZeneca Hellas, 03.2020-03.2023
Medical Manager Breast & Skin cancer, Roche Hellas 12.2014-03.2020
Medical Science Liaison, Oncology & Hematology Medical Division, Boehringer-Ingelheim Hellas, 07.2013-11.2014
Επιμελήτρια Παθολόγος Ογκολόγος, Γενικό Αντικαρκινικό Νοσοκομείο Πειραιά ΜΕΤΑΞΑ, 04.2012-04.2013
Ειδικευόμενη Παθολογικής Ογκολογίας, Θεραπευτική Κλινική Πανεπιστημίου Αθηνών & Ομώνυμο Εργαστήριο Ιατρικής Σχολής– ΓΝΑ “Αλεξάνδρα”, 02.2008-02.2011
Ειδικευόμενη Αιματολογίας και Παθολογίας, Πανεπιστημιακό Γενικό Νοσοκομείο "Αττικόν" και 417 Νοσηλευτικό Ίδρυμα Μετοχικού Ταμείου Στρατού, ΝΙΜΤΣ, 02.2005-02.2008
Υπηρεσία αγροτικού ιατρείου Αιανής, Περιφερικό Κέντρο Υγείας Σερβίων, Μαμάτσειο Γενικό Νοσοκομείο Κοζάνης, 10.2001-05.2003

ΜΕΛΟΣ ΕΤΑΙΡΕΙΩΝ, ΣΥΝΤΑΚΤΙΚΗΣ ΕΠΙΤΡΟΠΗΣ ΠΕΡΙΟΔΙΚΩΝ

ΕΡΕΥΝΗΤΙΚΑ ΠΡΟΓΡΑΜΜΑΤΑ

ΤΙΜΗΤΙΚΕΣ ΔΙΑΚΡΙΣΕΙΣ

Από το Ίδρυμα Κρατικών Υποτροφιών για την επίδοση κατά το Ακαδημαϊκό Έτος 1995-1996
Από το Ίδρυμα Κρατικών Υποτροφιών για την επίδοση κατά το Ακαδημαϊκό Έτος 1999-2000
Τιμητική Διάκριση για τη σειρά αποφοίτησης από την Ιατρική Σχολή του Παν/μίου Πατρών. Ακαδ. έτος 2000-2001
Έπαινος από την Ελληνική Ακαδημία Ογκολογίας για την επίδοση στα μαθήματα του 1ου κύκλου Σπουδών, Αθήνα 2007
2ο βραβείο poster/παρουσιάσεων στο 1st Mediterranean Multidisciplinary Oncology Forum. Athens, 10-13 September 2009
Υποτροφία Εσωτερικού από την Εταιρεία Ογκολόγων Παθολόγων Ελλάδας για την εκπόνηση της διατριβής, 2009
Υποτροφία Eξωτερικού από την Εταιρεία Ογκολόγων Παθολόγων Ελλάδας για μετεκπαίδευση και έρευνα στη Γαλλία, Παρίσι, Hopital Europeéne Georges Pompidou, INSERM 674, 2010

ΔΗΜΟΣΙΕΥΣΕΙΣ

Aristotle Bamias, George Lainakis, Efstathios, Manios, Eleni Koroboki, Alexandra Karadimou, Nikos Zakopoulos, Meletios A.Dimopoulos.Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma (RCC) treated with TKIs? J Clin Oncol. 2009, 27:2567-9
Alexandra Karadimou, D. Korkolis, K. Vasilikos, Meletios A. Dimopoulos, Aristotle Bamias. ‘Rapidly progressive, life threatening, testicular cancer. Emphasis in treatment. Forum of Clinical Oncology’. Official J. of the Hellenic Society of Medical Oncology.2009, 8(1-2):40-45
Karadimou A., Sereti E., Lainakis G., Tsiatas, M., Gyftaki R., Gavalas N., Dimopoulos A., Bamias A. Changes in lymphocytic populations and autoantibodies resulting from sunitinib treatment of metastatic renal cell carcinoma (mRCC ).15 ECCO -34 ESMO Multidisciplinary Congress 20-24 September 2009, Berlin. E.J.C. supplements Vol.7/2 (2009):435.
Alexandra Karadimou, Meletios A. Dimopoulos, Aristotle Bamias. The role of high- dose chemotherapy in the treatment of testicular cancer Journal of Urology. 2010:2 25-30 DOI 10.2147/OAJU.S6571
George Bozas, Evangelos Terpos, DimitraGika, Alexandra Karadimou, Meletios A. Dimopoulos, Aristotle Bamias. Pre- chemotherapy serum levels of CD105, TGF- β2 and VEGF are associated with prognosis in patients with advanced epithelial ovarian cancer treated with cytoreductive surgery and platinum-based chemotherapy. Int J Gynecol Cancer. 2010 Feb;20(2):248- 54.
Aristotelis Bamias, Alexandra Karadimou, Sofia Lampaki, George Lainakis, Lia Malettou, Eleni Timotheadou, Kostas Papazisis, Charalambos Andreadis, Loukas Kontovinis, Ioannis Anastasiou, Kostas Stravodimos, Ioannis Xanthakis, Andreas Skolarikos, Christos Christodoulou, Kostas Syrigos, Christos Papandreou, Evangelia Razi, Urania Dafni, George Fountzilas, Meletios A. Dimopoulos. Prognostic Stratification οf Patients With Advanced Renal Cell Carcinoma Treated With Sunitinib.Comparison With The Memorial Sloan-Kettering Prognostic Factors Model. BMC Cancer 2010,10:45
Karadimou, M. Tsiatas, N. Gavalas, G. Lainakis, E. Terpos, M. A. Dimopoulos, A.Bamias. Changes in lymphocytic populations and autoantibodies resulting from sunitinib treatment of metastatic renal cell carcinoma (mRCC). 2010 ASCO Annual Meeting. Chicago llinois, 4-8 June 2010 J Clin Oncol 28, 2010 (suppl; abstr e15085).
Bamias, N. Nikitas, A. Karadimou, D. Gika, V. Karavasilis, E. C. Briasoulis, M. Chrisofos, S. Murray, D. G. Pectasides, M. A. Dimopoulos. ERCC1 polymorphisms in patients with advanced bladder cancer treated with platinum-based chemotherapy.2010 ASCO Annual Meeting. Chicago Illinois, 4-8 June 2010 J Clin Oncol 28, 2010 (suppl; abstr e15066)
Ioannis Mountzios, Evangelos Bournakis, Andreas Varkaris, Sijin Wen, Michael Chrysofos, Charalambos Deliveliotis, Christos Alamanis, Ioannis Anastasiou, Constantine Constantinides, Alexandra Karadimou, Marinos Tsiatas, Aristotelis Bamias, Meletios Dimopoulos, Eleni Efstathiou. Intermittent Docetaxel Chemotherapy in Castrate-Resistant Prostate Cancer Patients. Urology.2011 Mar;77(3):682-7. Epub 2011 Jan 22 Alexandra Karadimou, Evangelos Lianos, Dimitrios Pectasides, MeletiosA. Dimopoulos,
Aristotle Bamias. Efficacy of methotrexate/vinblastine/doxorubicin/cisplatin combination in gemcitabine- pretreated patients with advanced urothelial cancer: A retrospective analysis. Journal of Urology 2010:2 193 – 199 DOI 10.2147/OAJU.S13122
Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin- Colonna F, Lacerda K, Karadimou A, Badoual C, Tedgui A, Fridman WH, Oudard S. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011 Mar;30(1):83-95
Alexandra Karadimou, Georgios Lainakis, Athanasios Maletios Dimopoulos, Aristoteli Bamias. Bevacizumab in the treatment of metastatic renal cell carcinoma (mRCC). FCO Jan 2011 (50-57)
Kontovinis L, Laschos K, Karadimou A, Andreadis C, Bamias A, Paraskevopoulos P,Dimopoulos M, Papazisis K. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Med Oncol. 2012 Jun;29(2):750-4. doi: 10.1007/s12032-010-9815-6. Epub 2011 Jan 30.
Gavalas NG, Karadimou A, Dimopoulos MA, Bamias A Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.Clin Dev Immunol. 2010;2010:791603. Epub 2011 Jan 24.
Benoit Beuselinck, Jacques Medioni, Pascal Wolter, Aurore Blesius, Alexandra Karadimou, Patrick Schöffski, Bernard Escudier, Jessica Zucman-Rossi, Robert Paridaens and Stéphane Oudard. Fuhrman grade and concomitant bisphosphonates as additional prognostic factors in metastatic renal cell carcinoma with bone metastases J Clin Oncol 29: 2011 (suppl 7; abstr 388)
Bamias, A. Karadimou, S. Lampaki, G. Aravantinos, I. Xanthakis, C. Papandreou,G. Lainakis, F. Zagouri, N. Soupos, E. Kostouros, E. Samantas, C. Hatzimouratidis, C. Konstantinidis, C. Deliveliotis, D. G. Pectasides, G. Fountzilas, M. A. Dimopoulos. Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer. 2011 ASCO Annual Meeting. J Clin Oncol 29: 2011 (suppl; abstr 4510)
F. Zagouri, A. Ziogas, N. Gavalas, M. Tsiatas, O. Tsitsilonis, E. Politi, C. Liakou, A. Karadimou, K. Arapini, E. Terpos, M. A. Dimopoulos, A. Bamias.The effect of VEGF on T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. J Clin Oncol 29: 2011 (suppl; abstr e15552)
Bamias A, Manios E, Karadimou A, Michas F, Lainakis G, Constantinidis C, Deliveliotis C, Zakopoulos N, Dimopoulos M. The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renalcancer. Eur J Cancer. volume 47, Issue 11, July 2011, p1660-1668
Aristotelis Bamias, Alexandra Karadimou, Nikos Soupos, Maria Sotiropoulou, Flora Zagouri, Dimitris Haidopoulos, Nikos Thomakos, Alexandros Rodolakis, Aristidis Antsaklis, Meletios A Dimopoulos,. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience. Gynecol Oncol. 2011 Oct;123(1):37-42. doi:10.1016/j.ygyno.2011.06.033. Epub 2011 Jul
Benoit Beuselinck, Alexandra Karadimou, Gabrielle Couchy, Bart Claes, Diether Lambrechts, Joost Berkers, Robert Paridaens, Patrick Schöffski, Jessica Zucman-Rossi and Stéphane Oudard. ABCB-1 and VEGFR-3 single nucleotide polymorphisms (SNPs) and outcome on sunitinib (SUN) treatment in metastatic clear cell renal cell carcinoma (RCC). E. J. C. supplements
Bamias A., Bamia C., Karadimou A., Soupos N., Zagouri F., Rodolakis A., Haidopoulos D., Vlahos G., Thomakos N., Antsaklis A., Dimopoulos M-A. A risk- adapted strategy of adjuvant paclitaxel/carboplatin in early stage ovarian cancer: time-dependent effect of 4 vs. 6 cycles on outcome. Oncology 2011;81(5-6):365- 71. doi: 10.1159/000334230. Epub 2012 Jan 13.
Nikos Gavalas, Marinos Tsiatas, Apostolos Ziogas, Alexandra Karadimou, Ekaterini Politi, Evangelos Terpos, Urania Tsitsilonis, Meletios Dimopoulos, Areistotle Bamias. VEGF suppressed T lympocytes from ovarian cancer patients through VEGFR2 expression upon activation. Int. J. Cancer: 128, Supplement 1, 35–49 (2011)
Alexandra Karadimou, Magdalini Migou, Afroditi Economidi, Alexandros Stratigos, Christos Kittas, Meletios A. Dimopoulos, Aristotle Bamias. Leukocytoclastic vasculitis after long term treatment with sunitinib: A case report. Case Reports in Oncology.Case Rep Oncol 2011;4:385-391 (DOI: 10.1159/000331419)
B. Beuselinck, A. Karadimou, G. Couchy, B. Claes, D. Lambrechts, J. Berkers, R. Paridaens, P. Schoffski, H. Van Poppel, P. Wolter, M. Arnaud, E. Lerut, B. Laguerre, C.Theodore, C. Linassier, R. Delva, E. Sevin, F. Goldwasser, J. Zucman-Rossi, S. Oudard. A pharmacogenomic scoring system predicting median time-to-progression (mTTP) on sunitinib (SUN) as first line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO-GU. 2-4 February 2012 San Francisco J Clin Oncol 2012 (suppl ahead of print)
Benoit Beuselinck, Pascal Wolter, Alexandra Karadimou, Reza Elaidi, Herlinde Dumez, Aljosja Rogiers, Thomas Van Cann, Ludo Willems, Jean-Jacques Body, Joost Berkers, Hendrik Van Poppel, Evelyne Lerut, Philip Debruyne, Robert Paridaens, Patrick Schöffski. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. British Journal of Cancer 107, pages1665–1671 (2012)
Yann-Alexandre Vano, Benoit Beuselinck, Pascal Wolter, Corine Teghom, Philip De Bruyne, Alexandra Karadimou, Evelyne Lerut, Robert Paridaens, Patrick Schöffski, Stéphane Oudard. Prognostic impact of baseline serum c- reactive protein in metastatic renal cell carcinoma treated with sunitinib. POSTER PRESENTATION. ASCO-GU 14-16 February 2013, Orlando, Florida. BJU Int. 2014 Jul;114(1):81-9. doi: 10.1111/bju.12494. Epub 2014 Jan 15.
Bamias A, Dafni U, Karadimou A, Timotheadou E, Aravantinos G, Psyrri A, Xanthakis I, Tsiatas M, Koutoulidis V, Constantinidis C, Hatzimouratidis C, Samantas E, Visvikis A, Chrisophos M, Stravodimos K, Deliveliotis C, Eleftheraki A, Pectasides D, Fountzilas G, Dimopoulos MA. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol. 2013 Apr;24(4):1011-7. doi: 10.1093/annonc/mds583. Epub 2012 Nov 7.
Nikitas N, Karadimou A, Tsitoura E, Soupos N, Tsiatas M, Karavasilis V, Pectasides D, Pavlidis N, Chrisofos M, Adamakis I, Murray S, Fountzilas G, Dimopoulos MA, Bamias A. Association of ERCC1 SNPs with outcome in platinum- treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study. Pharmacogenomics.2012 Nov;13(14):1595-607. doi: 10.2217/pgs.12.162.
Alexandra Karadimou, Thomas Makatsoris. NETs: Diagnostic challenge and therapeutic opportunity. J anuary 2013 Forum of Clinical Oncology 4(2):32-46
Beuselinck, Karadimou, Lambrechts, Claes, Wolter, Couchy, Berkers, Van Poppel, Paridaens, Schöffski, Mejean, Verkarre, Lerut, Joly, Lebret, Gravis, Deplanque, Descazeaud, RIOUX-LECLERCQ, Molinie, Patard, Teghom, Elaidi, Zucman-Rossi, Oudard. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis. Br J Cancer. 2013 Mar 5;108(4):887-900. doi: 10.1038/bjc.2012.548.
Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, de la Taille A, Tourani JM, Bigot P, Linassier C, Négrier S, Berger J, Patard JJ, Zucman- Rossi J, Oudard S. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.Br J Cancer. 2013 Mar 5;108(4):887- 900. doi: 10.1038/bjc.2012.548.
Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J, Debruyne PR, Van Poppel H, Joniau S, Lerut E, Strijbos M, Dumez H, Paridaens R, Van Calster B, Schöffski P. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int. 2014 Jul;114(1):81-9. doi: 10.1111/bju.12494. Epub 2014 Jan 15.
Alexandra Karadimou, Nikos Gavalas, Marinos Tsiatas, Eleni Sereti, Paraskevi- Sofia Trachana, Maria Spyropoulou-Vlachou, Eleni Karga, Evangelos Terpos, Ourania Tsitsilonis, Meletios A. Dimopoulos, Aristotelis Bamias. Pre-treatment status and changes in autoantibodies, lymphocytic populations, cytokines and VEGF during sunitinib treatment of metastatic renal cell carcinoma (mRCC). Translational Medicine 2014, 4:123, doi: 10.4172/2161-1025.1000124
Amalia Sofianidi, Alexandra Karadimou, Andriani Charpidou, Konstantinos N.Syrigos. The Gap of Health Inequalities Amongst Lung Cancer Patients of Different Socioeconomic Status: A Brief Reference to the Greek Reality. Cancers 2024, 16(5), 906; https://doi.org/10.3390/cancers16050906 (registering DOI)
Abstracts σε Εθνικά Συνέδρια: 14
Abstracts σε Διεθνή Συνέδρθια: 18
11th International Conference St. Gallen, Switzerland, 11-14 March 2009. Weekly docetaxel with or without gemcitabine as second line chemotherapy in paclitaxel pretreated patients with metastatic breast cancer: A randomized phase II study conducted by the Hellenic Co- operative oncology group. F.Zagouri, A.Bamias, P. Papakostas, A. Karadimou, E. Bournakis, M. Dimopoulos, G. Fountzilas, C. A. Papadimitriou.
1st Mediterranean Multidisciplinary Oncology Forum. 10-13 September 2009 Athens. Changes in lymphocytic populations and autoantibodies resulting from sunitinib treatment of metastatic renal cell carcinoma (mRCC ). Karadimou A., Gavalas N., Sereti E., Tsiatas M., Gyftaki R., Lainakis G., Dimopoulos A., Bamias A.
1st Mediterranean Multidisciplinary Oncology Forum. 10-13 September 2009 Athens. Proffered Paper Clinical Factors associated with outcome in patients with advanced renal cell carcinoma treated with sunitinib. An analysis by the Hellenic Cooperative Oncology Group. Bamias A., Lampaki S., Karadimou A., Lainakis G., Maletou L., Timotheadou E., Papazisis K., Andreadis C., Kontovinis L., Anastasiou I., Stravodimos K., Xanthakis I., Skolarikos A., Christodoulou C., Syrigos K., Papandreou C., Razi E., Fountzilas G., Dimopoulos A.
15 ECCO - 34 ESMO Multidisciplinary Congress 20-24 September 2009, Berlin. Changes in lymphocytic populations and autoantibodies resulting from sunitinib treatment of metastatic renal cell carcinoma (mRCC ) Karadimou A., Sereti E., Lainakis G., Tsiatas M., Gyftaki R., Gavalas N. DimopoulosA. , Bamias A. E. J. C. supplements Vol.7/2 (2009):435
2nd European Multidisciplinary Meeting on Urological Cancers. Embracing Excellence in Prostate, Bladder and Kidney Cancer. 27-29 November 2009, Barcelona, Spain. Changes in lymphocytic populations and autoantibodies resulting from sunitinib treatment of metastatic renal cell carcinoma (mRCC) Karadimou A., Sereti E., Gavalas N., Tsiatas M., Dimopoulos A., Bamias A.
2nd European Multidisciplinary Meeting on Urological Cancers. Embracing Excellence in Prostate, Bladder and Kidney Cancer. 27-29 November 2009, Barcelona, Spain. Clinical Factors associated with outcome in patients with advanced renal cell carcinoma treated with sunitinib. Karadimou A., Lampaki S., Lainakis G., Papazisis K., Andreadis C., Xanthakis I., Christodoulou C., Syrigos K., Papandreou C., Fountzilas G., Dimopoulos A., Bamias A.
16th International meeting of the European Society of Gynaecological Oncology. Belgrade, Servia, October 11-14, 2009. High-dose Melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer.F. Zagouri, A. Karadimou, M. Tsiatas, E. Bournakis, N. Nikitas, J. Handzinikolaou, M. A. Dimopoulos, C. A. Papadimitriou.
16th International meeting of the European Society of Gynaecological Oncology. Belgrade, Servia, October 11-14, 2009 Paclitaxel, Topotecan and Carboplatin in metastatic endometrial carcinoma: A Hellenic co-operative oncology group study. G. Lainakis, G. Fountzilas, D. Bafaloukos, M. Tsiatas, H. Kalofonos, D. Pectasides, G. Aravantinos, A. Karadimou, M.A. Dimopoulos, C.A., Papadimitriou. Hellenic Co- operative Oncology Group 2010
ASCO Annual Meeting. Chicago Illinois, 4-9 June 2010 Changes in lymphocytic populations and autoantibodies resulting from sunitinib treatment of metastatic renal cell carcinoma (mRCC). A. Karadimou, M. Tsiatas, N. Gavalas, G. Lainakis, E. Terpos, M.A. Dimopoulos, A. Bamias. J Clin Oncol 28, 2010 (suppl; abstr e15085) 2010
ASCO Annual Meeting. Chicago Illinois, 4-8 June 2010 ERCC1 polymorphisms in patients with advanced bladder cancer treated with platinum-based chemotherapy. A. Bamias, N. Nikitas, A. Karadimou, D. Gika, V. Karavasilis, E. C. Briasoulis, M. Chrisofos, S. Murray, D. G. Pectasides, M. A. Dimopoulos. J Clin Oncol 28, 2010 (suppl; abstr e15066) Excellence in Oncology. 18-20 November 2010, Athens. VEGF suppressed T lympocytes from ovarian cancer patients through VEGFR2 expression upon activation. Nikos Gavalas, Marinos Tsiatas, Apostolos Ziogas, Alexandra Karadimou, Ekaterini Politi, Evangelos Terpos, Urania Tsitsilonis, Meletios Dimopoulos, Aristotle Bamias. Int. J. Cancer: 128, Supplement 1, 35–49 (2011)
ASCO-GU Orlando 11-13 February 2011. Fuhrman grade and concomitant bisphosphonates as additional prognostic factors in metastatic renal cell carcinoma with bone metastases Benoit Beuselinck, Jacques Medioni, Pascal Wolter, Aurore Blesius, Alexandra Karadimou, Patrick Schöffski, Bernard Escudier, Jessica Zucman-Rossi, Robert Paridaens and Stéphane Oudard. J Clin Oncol 29: 2011 (suppl 7; abstr 388)
ASCO Annual Meeting 3-7 June 2011 (oral presentation) Bamias, A. Karadimou, S. Lampaki, G. Aravantinos, I. Xanthakis, C. Papandreou, G. Lainakis, F. Zagouri, N. Soupos, E. Kostouros, E. Samantas, C. Hatzimouratidis, C. Konstantinidis, C. Deliveliotis, D. G. Pectasides, G. Fountzilas, M. A. Dimopoulos. Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer. J Clin Oncol 29: 2011 (suppl; abstr 4510) ASCO
Annual Meeting 3-7 June 2011. F. Zagouri, A. Ziogas, N. Gavalas, M. Tsiatas, O. Tsitsilonis, E. Politi, C. Liakou, A. Karadimou, K. Arapini, E. Terpos, M. A. Dimopoulos, A. Bamias. The effect of VEGF on T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. J Clin Oncol 29: 2011 (suppl; abstr e15552) ECCO 36. 23-27 September 2011 Stockholm. Poster Discussion Session. Benoit Beuselinck, Alexandra Karadimou, Gabrielle Couchy, Bart Claes, Diether Lambrechts, Joost Berkers, Robert Paridaens, Patrick Schöffski, JessicaZucman- Rossi and Stéphane Oudard. ABCB-1 and VEGFR-3 single nucleotide polymorphisms (SNPs) and outcome on sunitinib (SUN) treatment in metastatic clear cell renal cell carcinoma (RCC). E. J. C. supplements. ASCO-GU. 2-4 February 2012 San Francisco B. Beuselinck, A. Karadimou, G. Couchy, B. Claes, D. Lambrechts, J. Berkers, R. Paridaens, P. Schoffski, H. Van Poppel, P. Wolter, M. Arnaud, E. Lerut, B. Laguerre, C. Theodore, C. Linassier, R. Delva, E. Sevin, F. Goldwasser, J. Zucman-Rossi, S. Oudard. A pharmacogenomic scoring system predicting median time-to-progression (mTTP) on sunitinib (SUN) as first line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2012.
27th Annual EAU Congress 24-28 February 2012 Paris France. B. Beuselinck, A. Karadimou, G. Couchy, B. Claes, D. Lambrechts, J. Berkers, R. Paridaens, P. Schoffski, H. Van Poppel, P. Wolter, M. Arnaud, E. Lerut, B. Laguerre, C. Theodore, C. Linassier, R. Delva, E. Sevin, F. Goldwasser, J. Zucman-Rossi, S. Oudard. A pharmacogenomic scoring system predicting median time-to-progression (mTTP) on sunitinib (SUN) as first line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC). Oral presentation.
ASCO-GU 14-16 February 2013, Orlando, Florida.Prognostic impact of baseline serum c- reactive protein in metastatic renal cell carcinoma treated with sunitinib. Yann- Alexandre Vano, Benoit Beuselinck, Pascal Wolter, Corine Teghom, Philip De Bruyne, Alexandra Karadimou, Evelyne Lerut, Robert Paridaens, Patrick Schöffski, Stéphane Oudard. Poster presentation.